Hormone replacement therapy
AssigneeWyeth
InventorJames H. Pickar
Life of this patent
Estimating the term…
Abstract
This invention relates to methods for providing hormone replacement therapy in perimenopausal, menopausal, and postmenopausal women through the sequential administration of combinations of conjugated estrogens and trimegestone.
Claims60
A method of treating or inhibiting menopausal or postmenopausal disorders in a perimenopausal, menopausal, or postmenopausal woman in need thereof, which comprises orally providing to said woman continuously and uninterruptedly for 28 days over a 28-day treatment cycle,
- a first phase of a daily dosage of 0.625 mg conjugated estrogens, wherein the same dosage is of conjugated estrogens is provided for 10-18 days of the treatment cycle, beginning on day 1 of the treatment cycle, and
- a second phase of a combination of a daily dosage of 0.625 mg conjugated estrogens and 0.0625-0.25 mg trimegestone, wherein the same dosage of the combination is provided for 10-18 days of the treatment cycle, beginning on the day following the completion of the first phase.
A method of treating or inhibiting vasomotor symptoms in a perimenopausal, menopausal, or postmenopausal woman in need thereof, which comprises orally providing to said woman continuously and uninterruptedly for 28 days over a 28-day treatment cycle,
- a first phase of a daily dosage of 0.625 mg conjugated estrogens, wherein the same dosage is of conjugated estrogens is provided for 10-18 days of the treatment cycle, beginning on day 1 of the treatment cycle, and
- a second phase of a combination of a daily dosage of 0.625 mg conjugated estrogens and 0.0625-0.25 mg trimegestone, wherein the same dosage of the combination is provided for 10-18 days of the treatment cycle, beginning on the day following the completion of the first phase.
A method of inhibiting or retarding bone demineralization or treating or inhibiting osteoporosis in a perimenopausal, menopausal, or postmenopausal woman in need thereof, which comprises orally providing to said woman continuously and uninterruptedly for 28 days over a 28-day treatment cycle,
- a first phase of a daily dosage of 0.625 mg conjugated estrogens, wherein the same dosage is of conjugated estrogens is provided for 10-18 days of the treatment cycle, beginning on day 1 of the treatment cycle, and
- a second phase of a combination of a daily dosage of 0.625 mg conjugated estrogens and 0.0625-0.25 mg trimegestone, wherein the same dosage of the combination is provided for 10-18 days of the treatment cycle, beginning on the day following the completion of the first phase.
A method of treating or inhibiting vaginal or vulvar atrophy;
- atrophic vaginitis;
- vaginal dryness;
- pruritus;
- dyspareunia;
- dysuria;
- frequent urination;
- urinary incontinence;
- urinary tract infections in a perimenopausal, menopausal, or postmenopausal woman in need thereof, which comprises orally providing to said woman continuously and uninterruptedly for 28 days over a 28-day treatment cycle,
- a first phase of a daily dosage of 0.625 mg conjugated estrogens, wherein the same dosage is of conjugated estrogens is provided for 10-18 days of the treatment cycle, beginning on day 1 of the treatment cycle, and
- a second phase of a combination of a daily dosage of 0.625 mg conjugated estrogens and 0.0625-0.25 mg trimegestone, wherein the same dosage of the combination is provided for 10-18 days of the treatment cycle, beginning on the day following the completion of the first phase.
A method of lowering cholesterol, Lp(a), or LDL levels;
- inhibiting or treating hypercholesteremia;
- hyperlipidemia;
- cardiovascular disease;
- atherosclerosis;
- peripheral vascular disease;
- restenosis, vasospasm;
- or inhibiting vascular wall damage from cellular events leading toward immune mediated vascular damage, in a perimenopausal, menopausal, or postmenopausal woman in need thereof, which comprises orally providing to said woman continuously and uninterruptedly for 28 days over a 28-day treatment cycle,
- a first phase of a daily dosage of 0.625 mg conjugated estrogens, wherein the same dosage is of conjugated estrogens is provided for 10-18 days of the treatment cycle, beginning on day 1 of the treatment cycle, and
- a second phase of a combination of a daily dosage of 0.625 mg conjugated estrogens and 0.0625-0.25 mg trimegestone, wherein the same dosage of the combination is provided for 10-18 days of the treatment cycle, beginning on the day following the completion of the first phase.
A method of treating or inhibiting free radical involvement in the development of cancers, central nervous system disorders, Alzheimer's disease, bone disease, aging, inflammatory disorders, peripheral vascular disease, rheumatoid arthritis, autoimmune diseases, respiratory distress, emphysema, prevention of reperfusion injury, viral hepatitis, chronic active hepatitis, tuberculosis, psoriasis, systemic lupus erythematosus, amyotrophic lateral sclerosis, aging effects, adult respiratory distress syndrome, central nervous system trauma and stroke, or injury during reperfusion procedures in a perimenopausal, menopausal, or postmenopausal woman in need thereof, which comprises orally providing to said woman continuously and uninterruptedly for 28 days over a 28-day treatment cycle,
- a first phase of a daily dosage of 0.625 mg conjugated estrogens, wherein the same dosage is of conjugated estrogens is provided for 10-18 days of the treatment cycle, beginning on day 1 of the treatment cycle, and
- a second phase of a combination of a daily dosage of 0.625 mg conjugated estrogens and 0.0625-0.25 mg trimegestone, wherein the same dosage of the combination is provided for 10-18 days of the treatment cycle, beginning on the day following the completion of the first phase.
A method of treating or inhibiting dementias, neurodegenerative disorders, and Alzheimer's disease;
- providing neuroprotection or cognition enhancement in a perimenopausal, menopausal, or postmenopausal woman in need thereof, which comprises orally providing to said woman continuously and uninterruptedly for 28 days over a 28-day treatment cycle,
- a first phase of a daily dosage of 0.625 mg conjugated estrogens, wherein the same dosage is of conjugated estrogens is provided for 10-18 days of the treatment cycle, beginning on day 1 of the treatment cycle, and
- a second phase of a combination of a daily dosage of 0.625 mg conjugated estrogens and 0.0625-0.25 mg trimegestone, wherein the same dosage of the combination is provided for 10-18 days of the treatment cycle, beginning on the day following the completion of the first phase.
A method of minimizing or reducing levels of breast pain in a woman receiving hormone replacement therapy, which comprises orally providing to said woman continuously and uninterruptedly for 28 days over a 28-day treatment cycle,
- a first phase of a daily dosage of 0.625 mg conjugated estrogens, wherein the same dosage is of conjugated estrogens is provided for 10-18 days of the treatment cycle, beginning on day 1 of the treatment cycle, and
- a second phase of a combination of a daily dosage of 0.625 mg conjugated estrogens and 0.0625-0.25 mg trimegestone, wherein the same dosage of the combination is provided for 10-18 days of the treatment cycle, beginning on the day following the completion of the first phase.
A method of minimizing spotting or breakthrough bleeding;
- or achieving amenorrhea in a woman receiving hormone replacement therapy, which comprises orally providing to said woman continuously and uninterruptedly for 28 days over a 28-day treatment cycle,
- a first phase of a daily dosage of 0.625 mg conjugated estrogens, wherein the same dosage is of conjugated estrogens is provided for 10-18 days of the treatment cycle, beginning on day 1 of the treatment cycle, and
- a second phase of a combination of a daily dosage of 0.625 mg conjugated estrogens and 0.0625-0.25 mg trimegestone, wherein the same dosage of the combination is provided for 10-18 days of the treatment cycle, beginning on the day following the completion of the first phase.
A method of increasing bone mineral density in a perimenopausal, menopausal, or postmenopausal woman in need thereof, which comprises orally providing to said woman continuously and uninterruptedly for 28 days over a 28-day treatment cycle,
- a first phase of a daily dosage of 0.625 mg conjugated estrogens, wherein the same dosage is of conjugated estrogens is provided for 10-18 days of the treatment cycle, beginning on day 1 of the treatment cycle, and
- a second phase of a combination of a daily dosage of 0.625 mg conjugated estrogens and 0.0625-0.25 mg trimegestone, wherein the same dosage of the combination is provided for 10-18 days of the treatment cycle, beginning on the day following the completion of the first phase.
Dependencies are inferred from the claim text.